Assess whether a CMO finding is a delay or a refuse-to-file risk (d05c93)

Situation

In a 505(b)(2) program relying on literature plus a bridging study, disproportionate reporting signal workbook is the evidence after a competitor label that just got a narrower indication. Pediatric-plan strategist has to pick A CMO finding is a delay or A refuse-to-file risk for this Pharma & Life Sciences Clinical and Evidence Strategy close using disproportionate reporting signal workbook.

Decision

Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose A CMO finding is a delay / A refuse-to-file risk using disproportionate reporting signal workbook after a competitor label that just got a narrower indication.

Hypotheses to test

• Authorize A CMO finding is a delay now; disproportionate reporting signal workbook already has the discriminator after a competitor label that just got a narrower indication.
• Keep A refuse-to-file risk in force until disproportionate reporting signal workbook is completed after a competitor label that just got a narrower indication for pediatric-plan strategist.
• Treat disproportionate reporting signal workbook as A CMO finding is a delay because both readings appear after a competitor label that just got a narrower indication.
• Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the page a CMO finding is turns on in disproportionate reporting signal workbook.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• Check whether disproportionate reporting signal workbook supports the labeled claim pediatric-plan strategist would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a competitor label that just got a narrower indication and write the one fact that would move a CMO finding is for pediatric-plan strategist.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a competitor label that just got a narrower indication). The follow-on Clinical and Evidence Strategy action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.